Dantariincis A Clinical Stage Biotechnology Company Based In Thousand Oakscaliforniafounded In 2018The Company Specializes In Oncologydeveloping Targeted Therapeutics For Cancers And Serious Diseases Using Its Proprietary Targeted High Capacity Drug Conjugatet Hdcplatformthis Innovative Technology Enhances Drug Delivery And Efficacyallowing For A Higher Drug To Antibody Ratio Compared To Traditional Antibody Drug Conjugates Dantari S Pipeline Includes Several Promising Candidatesdan 222 Is Currently In Phase 1 Trials For Metastatic Her2 Negative Breast Cancershowing Encouraging Antitumor Activityother Candidates Include Dan 311A Preclinical Dual Targeting Adc For Breast Cancerand Dan 405Targeting Castration Resistant Prostate Cancerthe Company Is Well Supported By Notable Investorshaving Raised $47 Million In Its Series A Funding Roundwhich Positions It For Potential Collaborations In The Healthcare Sector
